Employment

Canon U.S.A., Inc. Recognized by Forbes as One of America's Best Midsize Employers in 2024

Retrieved on: 
Wednesday, March 6, 2024

Melville, NY, March 06, 2024 (GLOBE NEWSWIRE) -- Canon U.S.A., Inc., a leader in digital imaging solutions, is pleased to announce it has been recognized by Forbes as one of America’s Best Midsize Employers for 2024.

Key Points: 
  • Melville, NY, March 06, 2024 (GLOBE NEWSWIRE) -- Canon U.S.A., Inc., a leader in digital imaging solutions, is pleased to announce it has been recognized by Forbes as one of America’s Best Midsize Employers for 2024.
  • Forbes and Statista Inc. announced Canon’s inclusion in this prestigious ranking of companies, and the list is now live on the Forbes website.
  • This is the 9th year in a row Canon has been included on America’s Best Employers’ list.
  • Forbes and Statista selected America's Best Midsize Employers for 2024 based on independent surveys of more than 170,000 American employees working for companies with between 1,000 and 5,000 workers in the United States.

Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Retrieved on: 
Wednesday, March 6, 2024

WALTHAM, Mass., March 06, 2024 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals , Inc. (Nasdaq: APLS) today announced that the company approved the grant of equity awards to one new employee with a grant date of March 1, 2024, as equity inducement awards outside of the company's 2017 Stock Incentive Plan (but under the terms of the 2020 Inducement Stock Incentive Plan) and material to the employees’ acceptance of employment with the company.

Key Points: 
  • WALTHAM, Mass., March 06, 2024 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals , Inc. (Nasdaq: APLS) today announced that the company approved the grant of equity awards to one new employee with a grant date of March 1, 2024, as equity inducement awards outside of the company's 2017 Stock Incentive Plan (but under the terms of the 2020 Inducement Stock Incentive Plan) and material to the employees’ acceptance of employment with the company.
  • The equity awards were approved in accordance with Nasdaq Listing Rule 5635(c)(4).
  • The employee received 2,795 restricted stock units (RSUs).
  • Each RSU will vest as to 25% of the shares underlying the RSU award on the first anniversary of the grant date and as to an additional 25% of the shares underlying the RSU award annually thereafter, subject to each such employee's continued employment on each vesting date.

Madrigal Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Retrieved on: 
Wednesday, March 6, 2024

The equity awards were approved in accordance with Nasdaq Listing Rule 5635(c)(4).

Key Points: 
  • The equity awards were approved in accordance with Nasdaq Listing Rule 5635(c)(4).
  • The equity awards were granted as inducement material to Ms. Dier’s and the other employees’ acceptance of employment with the company.
  • Ms. Dier received options to purchase 13,353 shares of Madrigal’s common stock, 8,875 time-based restricted stock units and 8,875 market-based performance stock units (“MSUs”).
  • All restricted stock units granted vest in a 25% increment on each of the first through fourth anniversaries of the grant date.

Smart Prosperity Institute research identifies three priorities to seize the economic opportunity of mass timber in British Columbia

Retrieved on: 
Wednesday, March 6, 2024

However, stakeholders in British Columbia (BC) are exploring mass timber as a potential driver of economic growth.

Key Points: 
  • However, stakeholders in British Columbia (BC) are exploring mass timber as a potential driver of economic growth.
  • If this sector continues to grow, mass timber can be a source of investment and employment for rural and resource-dependent communities by invigorating the forestry industry and diversifying local economies.
  • The decline in the forestry sector has resulted in job losses across British Columbia, but a thriving mass timber sector could help generate novel growth opportunities in small Northern communities.
  • As of 2023, more than 350 mass timber projects have been built or are under construction across the province.

Fate Therapeutics Reports New Employee Inducement Award Under Nasdaq Listing Rule 5635(c)(4)

Retrieved on: 
Tuesday, March 5, 2024

SAN DIEGO, March 05, 2024 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune disorders, today announced that the Company granted a non-qualified stock option to one newly-hired employee to purchase a total of 40,000 shares of the Company’s common stock at an exercise price per share of $7.74, which was the closing price per share of the Company’s common stock as reported by NASDAQ on the grant effective date of March 1, 2024.

Key Points: 
  • SAN DIEGO, March 05, 2024 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune disorders, today announced that the Company granted a non-qualified stock option to one newly-hired employee to purchase a total of 40,000 shares of the Company’s common stock at an exercise price per share of $7.74, which was the closing price per share of the Company’s common stock as reported by NASDAQ on the grant effective date of March 1, 2024.
  • The option was approved by the Compensation Committee of the Company’s Board of Directors and granted under the Company’s Amended and Restated Inducement Equity Plan as an inducement material to the new employees entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4).
  • The option vests over four years, with 25% vesting on the one-year anniversary of the grant date and the remaining 75% percent vesting in approximately equal monthly installments over the following thirty-six months, subject to the employee being continuously employed by the Company through each vesting date.

Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Retrieved on: 
Tuesday, March 5, 2024

The foregoing stock options and RSUs were granted as material inducements to employment with Vor Bio in accordance with Nasdaq Listing Rule 5635(c)(4) and were granted under the Vor Biopharma Inc. 2023 Inducement Plan (the “Inducement Plan”).

Key Points: 
  • The foregoing stock options and RSUs were granted as material inducements to employment with Vor Bio in accordance with Nasdaq Listing Rule 5635(c)(4) and were granted under the Vor Biopharma Inc. 2023 Inducement Plan (the “Inducement Plan”).
  • The stock options have a ten-year term and an exercise price of $2.27 per share, which is equal to the closing price of Vor Bio’s common stock on March 1, 2024.
  • The RSUs will vest over a four-year period, with 25% of the shares vesting after 12 months and the remaining shares vesting quarterly over the following 36 months, subject to the employee’s continued employment with Vor Bio on such vesting dates.
  • The options and RSUs are subject to the terms and conditions of the Inducement Plan and the terms and conditions of an award agreement covering the grants.

Cartesian Therapeutics Announces New Employment Inducement Grant

Retrieved on: 
Tuesday, March 5, 2024

GAITHERSBURG, Md., March 05, 2024 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a clinical-stage biotechnology company developing mRNA cell therapies for the treatment of autoimmune diseases, today announced the granting of an inducement award to a new employee.

Key Points: 
  • GAITHERSBURG, Md., March 05, 2024 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a clinical-stage biotechnology company developing mRNA cell therapies for the treatment of autoimmune diseases, today announced the granting of an inducement award to a new employee.
  • On March 1, 2024, the Company issued to this employee an option to purchase 375,000 shares of the Company’s common stock with an exercise price of $0.69, the closing trading price of the Company’s common stock on the Nasdaq Global Market on the date of grant.
  • This option was granted pursuant to the Company’s Amended and Restated 2018 Employment Inducement Incentive Award Plan and was approved by the Company’s board of directors.
  • The option was granted under Rule 5635(c)(4) of the Nasdaq Listing Rules as an inducement material to the employee’s entry into employment with the Company.

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Retrieved on: 
Tuesday, March 5, 2024

WESTLAKE VILLAGE, Calif., March 05, 2024 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today reported the grant of an aggregate of 12,000 restricted stock units of Arcutis’ common stock to two newly hired employees.

Key Points: 
  • WESTLAKE VILLAGE, Calif., March 05, 2024 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today reported the grant of an aggregate of 12,000 restricted stock units of Arcutis’ common stock to two newly hired employees.
  • These awards were approved by the Compensation Committee of Arcutis’ Board of Directors and granted under the Arcutis Biotherapeutics, Inc. 2022 Inducement Plan, with a grant date of March 4, 2024, as an inducement material to the new employees entering into employment with Arcutis, in accordance with Nasdaq Listing Rule 5635(c)(4).
  • The restricted stock units vest over four years, with 25 percent vesting on each annual anniversary of the vesting commencement date, subject to the employee being continuously employed by Arcutis as of such vesting dates.

Resonance Consultancy Reveals Europe’s Best Cities for 2024

Retrieved on: 
Tuesday, March 5, 2024

LONDON, March 05, 2024 (GLOBE NEWSWIRE) -- Resonance is a leading adviser in tourism, real estate and economic development, and its annual Europe's Best Cities rankings quantify and benchmark the relative quality of place, reputation and competitive identity for the continent's urban centres.

Key Points: 
  • LONDON, March 05, 2024 (GLOBE NEWSWIRE) -- Resonance is a leading adviser in tourism, real estate and economic development, and its annual Europe's Best Cities rankings quantify and benchmark the relative quality of place, reputation and competitive identity for the continent's urban centres.
  • The Best Cities data is lauded as the world's most thorough annual city rankings, based on original methodology that analyses key statistics, user-generated reviews, social media and online activity.
  • The overall Best Cities rankings are determined by analysing the performance of each city for a wide range of factors that have historically shown positive correlations with attracting employment, investment and/or visitors to cities.
  • Based on each city's performance across our methodology, these are Europe's Top 10 Best Cities for 2024:

Abeona Therapeutics Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Retrieved on: 
Tuesday, March 5, 2024

CLEVELAND, March 05, 2024 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced it has granted equity awards to new non-executive employees who joined the Company.

Key Points: 
  • CLEVELAND, March 05, 2024 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced it has granted equity awards to new non-executive employees who joined the Company.
  • The equity awards were approved in accordance with Nasdaq Listing Rule 5635(c)(4).
  • On February 29, 2024, the Compensation Committee of Abeona’s Board of Directors granted restricted stock equity awards as a material inducement to employment to three individuals hired by Abeona, which equity awards relate to, in the aggregate, up to 25,500 restricted shares of Abeona common stock.
  • One-third of the shares subject to such restricted stock awards will vest yearly on each anniversary of the Grant Date, such that the shares subject to such restricted stock awards granted to each employee will be fully vested on the third anniversary of the Grant Date, in each case, subject to each employee’s continued employment with Abeona on the applicable vesting dates.